English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We herein, described the synthesis of some new  N -(thiazol-2-yl)benzamides of quinoxaline. All the synthesized compounds were evaluated for their  in vitro  anticancer activity against three human cancer cell lines including MCF-7 (breast cancer), A549 (lung cancer) and HepG2 (liver cancer). In this study, etoposide was used as a positive control. The results revealed that the compounds  6d, 6e, 6i, 6j  and  6m  exhibited promising activity against three cancer cell lines. Predominantly, compound  6i  displayed greater activity than the standard drug etoposide on MCF-7, A549 and HepG2 with IC 50  values of 0.95 ± 0.063, 1.32 ± 0.16 and 1.24 ± 0.10 µM respectively. The cell viability assay carried out toward a normal breast cell line (MCF-10A) for five potent compounds  6d, 6e, 6i, 6j , and  6m , did not exhibit significant cytotoxicity with IC 50  values above 85 µM for all compounds. Molecular docking studies of potent compounds  6d, 6e, 6i, 6j  and  6m  with DNA topoisomerase II revealed that they have a good affinity toward the target protein. In addition to this,  in silico  pharmacokinetic profile was achieved for the potent compounds  6d, 6e, 6i, 6j  and  6m  using SWISS/ADME and pkCSM, whereas  6d ,  6e  and  6i  compounds followed Lipinski, Ghose, Veber, Egan, and Muegge rules without any deviation.

Design and Synthesis of Some New N -(Thiazol-2-yl) Benzamides of Quinoxaline as DNA Topoisomerase II Targeting Anticancer Agents and ADMET